Financial reports
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
ARS
2022 FY
Annual report to shareholders
11 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
3 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
29 Mar 22
Current reports
8-K
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Mar 24
8-K
Entry into a Material Definitive Agreement
26 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Entry into a Material Definitive Agreement
22 Dec 23
8-K
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
2 Aug 23
8-K
Departure of Directors or Certain Officers
23 Jun 23
8-K
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
9 May 23
8-K
Other Events
28 Apr 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
29 Mar 24
S-8
Registration of securities for employees
29 Mar 24
S-8
Registration of securities for employees
22 Jun 23
SC TO-I/A
Issuer tender offer statement (amended)
31 May 23
SC TO-I/A
Issuer tender offer statement (amended)
9 May 23
S-3/A
Shelf registration (amended)
9 May 23
SC TO-I
Issuer tender offer statement
1 May 23
424B3
Prospectus supplement
14 Mar 23
S-3
Shelf registration
3 Mar 23
S-3
Shelf registration
3 Mar 23
Proxies
PRE 14A
Preliminary proxy
19 Apr 24
DEFA14A
Additional proxy soliciting materials
1 Jun 23
DEF 14A
Definitive proxy
11 May 23
DEF 14A
Definitive proxy
13 Mar 23
PRE 14A
Preliminary proxy
1 Mar 23
DEF 14A
Definitive proxy
9 Sep 22
PRE 14A
Preliminary proxy
30 Aug 22
DEFA14A
Additional proxy soliciting materials
31 May 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
Other
EFFECT
Notice of effectiveness
12 May 23
CORRESP
Correspondence with SEC
9 May 23
EFFECT
Notice of effectiveness
15 Mar 23
CORRESP
Correspondence with SEC
10 Mar 23
UPLOAD
Letter from SEC
8 Mar 23
UPLOAD
Letter from SEC
8 Mar 23
CT ORDER
Confidential treatment order
15 Jul 21
EFFECT
Notice of effectiveness
20 May 20
CORRESP
Correspondence with SEC
15 May 20
UPLOAD
Letter from SEC
13 May 20
Ownership
SC 13G
MILLENNIUM MANAGEMENT LLC
16 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Checkpoint Capital L.P.
14 Feb 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
29 Jan 24
4
Eric Trachtenberg
5 Jan 24
4
Darius Kharabi
5 Jan 24
4
Romulus K Brazzell
5 Jan 24
4
Mark T Iwicki
5 Jan 24
4
Mary Reumuth
5 Jan 24
4
Todd Bazemore
5 Jan 24